Anaplastic Astrocytoma - A Pipeline Analysis Report
- Published: Apr 2018
- Pages: 89
- SKU: IRTNTR22693
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
This pipeline analysis report provides detailed insights into the drug development landscape of the development of drug for anaplastic astrocytoma including molecules at pre-clinical, discovery, and other developmental stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as indications coverage, therapies employed, preferred route of administration, typed of molecules used, and targets for drugs under development.
Overview of the drug development pipeline for anaplastic astrocytoma
Anaplastic astrocytoma is a malignant brain tumor, which is caused by astrocytoma. Astrocytoma is mostly associated with certain hereditary issues including tuberous sclerosis, neurofibromatosis type I, and the LI-Fraumeni syndrome. People suffering from this tumor experience various symptoms including seizures, depression, focal neurological deficit, and headache. Technavio’s market research analysts have predicted that anaplastic astrocytoma market growth will be witnessed with the introduction of radiation therapy (RT) and chemotherapy as some of the most promising approaches to treat anaplastic astrocytoma, the global anaplastic astrocytoma market will witness growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase I development stage. For instance, sponsors such as Amgen developed AMG 595 and Boehringer Ingelheim developed Afatinib, which are under phase I stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the pre-clinical, phase III, and phase II/III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the phase II stage.
Anaplastic astrocytoma industry analysis: Companies covered
According to the anaplastic astrocytoma industry analysis, this report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of anaplastic astrocytoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Northwell Health
Therapeutic assessment of the drug development pipeline for anaplastic astrocytoma by the preferred route of administration
- Oral + IV
The oral route of administration (ROA) involves the administration of drug substances through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
Therapeutic assessment of the drug development pipeline for anaplastic astrocytoma by types of molecules used
- Small molecule
According to anaplastic astrocytoma industry insights, the majority of molecules that are currently in the drug development pipeline for anaplastic astrocytoma are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for anaplastic astrocytoma?
- What are the companies that are currently involved in the development of drug development molecules for anaplastic astrocytoma?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.